Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SLRX 
Salarius Pharmaceuticals Inc (SLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: SLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.82% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.57M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 1 | Beta 0.4 | 52 Weeks Range 0.71 - 55.05 | Updated Date 12/13/2025 |
52 Weeks Range 0.71 - 55.05 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate - | Actual -1.8137 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.91% | Return on Equity (TTM) -139.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2886348 | Price to Sales(TTM) 18.12 |
Enterprise Value 2886348 | Price to Sales(TTM) 18.12 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA 1.52 | Shares Outstanding 5862178 | Shares Floating 5519827 |
Shares Outstanding 5862178 | Shares Floating 5519827 | ||
Percent Insiders 0.64 | Percent Institutions 5.22 |
About Salarius Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2015-01-29 | CEO & Director Mr. Frederick E. Pierce II | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.salariuspharma.com |
Full time employees 2 | Website https://www.salariuspharma.com | ||
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.